Literature DB >> 19460283

Obstacles to the implementation of antiemetic guidelines.

Steven M Grunberg1.   

Abstract

Although guidelines help physicians deliver high quality clinical care, they will have minimal impact unless familiarity and adherence are achieved. Although nausea and vomiting are highly feared toxicities of chemotherapy that markedly decrease patient quality of life, modifications in physician behavior and improvements in standards of care, particularly in terms of preventing delayed emesis, have been slow. Variations in format, goals, physician education, and institutional education may all affect guideline implementation and state-of-the-art care. The relationship between these factors and the scientific basis of antiemetic guidelines must be considered to achieve optimal results and compliance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460283     DOI: 10.6004/jnccn.2009.0040

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  10 in total

1.  Antiemetic prescribing practices using a computerized physician order entry system.

Authors:  Kunal C Kadakia; Alexis D Leal; Drew K Seisler; Rui Qin; Kelliann C Fee-Schroeder; Darryl C Grendahl; Kristine M Sorgatz; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2013-09-13       Impact factor: 3.603

2.  Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.

Authors:  Shiying Yu; Thomas A Burke; Alexandre Chan; Hoon-Kyo Kim; Ruey Kuen Hsieh; Xichun Hu; Jin-Tung Liang; Ana Baños; Carmel Spiteri; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2014-08-13       Impact factor: 3.359

3.  Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine.

Authors:  Talha Badar; Jorge Cortes; Gautam Borthakur; Susan O'Brien; William Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Tapan Kadia; Rebeca Poku; Hagop Kantarjian; Gloria Mattiuzzi
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

Review 4.  A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Paul J Hesketh; Matti Aapro; Karin Jordan; Lee Schwartzberg; Snezana Bosnjak; Hope Rugo
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

5.  Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.

Authors:  Jessica P Hwang; Michael J Fisch; Anna S-F Lok; Hong Zhang; John M Vierling; Maria E Suarez-Almazor
Journal:  BMC Cancer       Date:  2013-11-09       Impact factor: 4.430

6.  Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial.

Authors:  Negah Chaabi Ahvazi; Simin Hemati; Mohamad Mohamadianpanah
Journal:  Adv Biomed Res       Date:  2015-10-29

Review 7.  NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.

Authors:  Helene Cawston; Francois Bourhis; Jennifer Eriksson; Pierfrancesco Ruffo; Paolo D'Agostino; Marco Turini; Lee Schwartzberg; Alistair McGuire
Journal:  Drugs Context       Date:  2017-03-24

8.  Effect of acupuncture in prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: study protocol for a randomized controlled trial.

Authors:  Qi-Wei Li; Ming-Wei Yu; Guo-Wang Yang; Xiao-Min Wang; Huan Wang; Chen-Xi Zhang; Na Xue; Wei-Ru Xu; Qi Fu; Zhong Yang; Lin Yang
Journal:  Trials       Date:  2017-04-20       Impact factor: 2.279

Review 9.  Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.

Authors:  Mary Lou Affronti; Joseph Bubalo
Journal:  Cancer Manag Res       Date:  2014-09-05       Impact factor: 3.989

10.  Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research.

Authors:  Qi-Wei Li; Ming-Wei Yu; Xiao-Min Wang; Guo-Wang Yang; Huan Wang; Chen-Xi Zhang; Na Xue; Wei-Ru Xu; Yi Zhang; Pei-Yu Cheng; Lin Yang; Qi Fu; Zhong Yang
Journal:  Chin Med       Date:  2020-06-03       Impact factor: 5.455

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.